In a phase 1 trial of 90 adults aged 55–75 (60 healthy, 30 with obesity and/or type 2 diabetes), three doses of adjuvanted GBS-AlpN vaccine caused mainly mild reactions and no related serious events; all but three vaccinees seroconverted to all four antigens by day 57.
RCTn = 90
Oostvogels et al. A randomised, double-blind, placebo-controlled phase I clinical trial to evaluate the safety, tolerability and immunogenicity of three doses of an adjuvanted group B Streptococcus vaccine in older adults aged 55 to 75